[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352125-105":59,"doc-detail-352125-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-of-novel-mrna-classifiers-to-stratify-preoperative-thyroid-tumor-risk","Development of Novel mRNA Classifiers to Stratify Preoperative Thyroid Tumor Risk","","Objective. Develop a preoperative risk classiﬁer to guide the extent of surgery in differentiated thyroid carcinomas (DTCs) under 4 cm. Design and setting. In silico study with validation using a retrospective cohort; genomic data repositories and an academic tertiary medical center. Methods. Create ClinicoTRanscriptomic (CTR) groups from TCGA using prognostic transcriptional groups and ATA risk groups; perform DGE and consensus clustering across FNA and annotated surgical cohorts, plus an independent surgical cohort. Results and conclusion. The POINT 144-gene classifier predicts genomic alterations and ATA risk, enabling biology-driven care.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-of-novel-mrna-classifiers-to-stratify-preoperative-thyroid-tumor-risk/352125/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-of-novel-mrna-classifiers-to-stratify-preoperative-thyroid-tumor-risk/352125.png","ImageObject",300,407,{"name":92,"@type":93},"LangkahRina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of the study?","Question",{"text":112,"@type":113},"To develop a preoperative risk classifier that helps guide the extent of surgery for differentiated thyroid carcinomas under 4 cm.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the novel ClinicoTRanscriptomic (CTR) groups constructed?",{"text":117,"@type":113},"By using prognostic transcriptional groups and American Thyroid Association (ATA) risk groups from TCGA to form CTR groups, then applying differential gene expression and consensus clustering.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the key outcome of the POINT 144-gene classifier?",{"text":121,"@type":113},"It predicts genomic alterations and aligns with ATA risk categories in independent data sets, including fair agreement in the surgical cohort and strong negative predictive value for ruling out high ATA risk.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352125,1792163782,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090893776,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Development of Novel mRNA Classiﬁers to Stratify Preoperative Thyroid Tumor Risk  \nThomas F. Barrett, MD 1* , Mohamed Jama, MS 1*, Mohammed Alshalalfa, PhD2*, Theresa Tharakan, MD, MSCI 1, Yangyang Hao, PhD2, Joshua P. Klopper, MD2,  \nTaylor B. Cavazos, PhD2, Ryan S. Jackson, MD 1,3, Patrik Pipkorn, MD 1,3, Jason T. Rich, MD 1,3, Paul A. Zolkind, MD 1,3, Douglas R. Adkins, MD3,4,  \nPeter Oppelt, MD3,4, Anthony J. Apicelli, MD, PhD3,5, Nikhil Rammohan, MD, PhD3,5, Taylor C . Brown, MD, MHS6, Sidharth V. Puram, MD, PhD 1,3, Sina Jasim, MD7, and  \nR. Alex Harbison, MD, MS 1,3   \nOtolaryngology–  \nHead and Neck Surgery  \n2026, Vol. 175(3) 578–586 © 2026 The Author(s) . Otolaryngology–Head and Neck Surgery published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngology–Head and Neck Surgery Foundation.  \nDOI: 10.1002/ohn.70333  \n[http://otojournal.org](http://otojournal.org)  \nAbstract  \nObjective. Develop a preoperative risk classiﬁer for guiding the extent of surgery in differentiated thyroid carcinomas (DTCs) under 4 cm.  \nStudy Design. In silico study, validation with retrospective cohort.  \nSetting. Genomic data repositories, academic tertiary medical center.  \nMethods. Prognostic transcriptional groups and American Thyroid Association (ATA) risk groups in The Cancer Genome Atlas (TCGA) were used to create novel ClinicoTRanscriptomic (CTR) groups. Differential gene expression (DGE) was performed. Consensus clustering was used to assess the reproducibility of genomic and histologic features in:  \n(1) Bethesda V/VI ﬁne-needle aspirates (FNA) from the Aﬁrma Genomic Sequencing Classiﬁer (GSC) database (GC cohort);  \n(2) thyroid carcinomas annotated by ATA histopathologic risk group (surgical cohort); (3) independent surgical cohort. Results. Within TCGA (n = 451), CTR-Low was enriched with BRAFV600E mutations. CTR-Intermediate was enriched in follicular cancers, while CTR-High had high rates of TERT promoter (TERTp) and BRAFV600E mutations. A 144 gene classiﬁer (PreOperative INdicator of Thyroid cancer progression [POINT]) was developed based on inter-CTRDGEs. Clustering of the GC cohort using POINT demonstrated similar genomic features with 3 groups characterized by BRAFV600E and ALK/NTRK/RET fusions, RAS mutations, or TERTp/BRAFV600E alterations. Agreement of POINTwith ATArisk group in the surgical cohort (n = 129) showed fair agreement (weighted κ = 0.25), NPV 0.89 for ruling out high ATA risk, and NNT 5.3 to avoid 1 completion thyroidectomy.  \nConclusion. The POINT classiﬁer is predictive of genomic alterations and ATA risk in independent data sets. This study advances precision oncology, shifting the paradigm from sizebased toward individualized, biology-driven care.  \nKeywords  \nAﬁrma, clustering, prognostic gene signature, thyroid cancer, thyroid nodule  \nReceived September 30, 2025; accepted May 18, 2026.  \n1 Department of Otolaryngology–Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA  \n2Veracyte Inc., South San Francisco, California, USA  \n3Robert Ebert and Greg Stubbleﬁeld Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine,  \nSt. Louis, Missouri, USA  \n4Division of Oncology, Washington University School of Medicine, St. Louis, Missouri, USA  \n5Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA  \n6Department of Surgery, Section of Surgical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA  \n7Department of Medicine, Division of Endocrinology, Washington University School of Medicine, St. Louis, Missouri, USA  \n*These authors contributed equally to this article.  \nThis article was presented at the AAO-HNSF 2025 Annual Meeting & OTO EXPO, October 11-14, Indianapolis, Indiana  \nCorresponding Author:  \nR. Alex Harbison, MD, MS, Washington University School of Medicine, Siteman Cancer Center, 660 S. Euclid Ave, Box 8115-029-08, St. Louis, MO 6311","cbCaiepS9PsOtRJa","https://ap.wps.com/l/cbCaiepS9PsOtRJa","pdf",2034339,"English","# Abstract\n## Objective\n## Study Design and Setting\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What is the main objective of the study?\",\"answer\":\"To develop a preoperative risk classifier that helps guide the extent of surgery for differentiated thyroid carcinomas under 4 cm.\"},{\"question\":\"How were the novel ClinicoTRanscriptomic (CTR) groups constructed?\",\"answer\":\"By using prognostic transcriptional groups and American Thyroid Association (ATA) risk groups from TCGA to form CTR groups, then applying differential gene expression and consensus clustering.\"},{\"question\":\"What is the key outcome of the POINT 144-gene classifier?\",\"answer\":\"It predicts genomic alterations and aligns with ATA risk categories in independent data sets, including fair agreement in the surgical cohort and strong negative predictive value for ruling out high ATA risk.\"}]","Development of Novel mRNA Classifiers to Stratify Preoperative Thyroid Tumor Risk | PDF",1790097811,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/776302edab6c4db9785e4a0f96786fa9.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8831fb3a58c1ee95d6521f597e4ebd70.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52fed89bdd86b51a3ad1835561d85a46.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5101ffff700a91f1ac6fd11ca1b20678.webp",980,1311]